Меню
Идёт набор NCT07224230

Physician-Modified Endografts for Complex Aortic Aneurysms and Thoracoabdominal Aneurysm Repair in High-Risk Patients

Без фазы С лечением Abdominal Aortic Aneurysms Thoracoabdominal Aneurysms Pararenal Aortic Aneurysm

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Physician Modified Endograft.
Кому может быть актуально
Состояния в реестре: Abdominal Aortic Aneurysms, Thoracoabdominal Aneurysms, Pararenal Aortic Aneurysm. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

This single-arm FDA-monitored protocol intends to broaden endovascular device applicability using physician-modifications in patients who A) Have anatomical conditions not amenable to endovascular repair using currently marketed grafts in the United States. B) Are at high risk for open surgical repair. C) Are high-risk subjects with previously placed endovascular devices and have developed failure of their previous devices. The use of physician-modified endografts aims to shift the seal zone proximally above the celiac artery in order to treat their complex or thoracoabdominal aneurysms in a minimally invasive fashion. These patients are considered too high risk to survive open surgical repair and do not meet anatomic criteria for the Gore Thoracoabdominal Multi Branch Endoprosthesis, which is currently the only FDA approved device in the US to treat these aneurysms. The primary objective is to evaluate safety and effective of physician modified endografts in the treatment of thorax-abdominal aneurysms and complex aortic aneurysms. For primary safety endpoints, mortality and major adverse events (MAE) will be analyzed at 30 days or in hospitalization (if this exceeds 30 days). Primary endpoints include the following: 1. Mortality related to primary aortic disease 2. Aneurysm rupture 3. All cause mortality For primary effectiveness endpoints, treatment success will be analyzed as the proportion of patients to achieve treatment success at 12 months. Treatment success is defined by a composite endpoint, which includes all of the following criteria: Technical success (defined as successful delivery and deployment of the physician modified endograft with perseveration of those branch vessels intended to be preserved, freedom from type I or type III endoleak, freedom from stent graft migration, freedom from aneurysm enlargement \>5mm, freedom from aneurysm rupture or conversion to open repair. Secondary objectives of the study include assessment of individual safety and effectiveness endpoints as follows: technical success, procedure success, mortality, major adverse events - specifically renal, cardia, pulmonary, gastrointestinal, and neurologic. Each endpoint will be analyzed separately. Secondary endpoints will be individually analyzed at 4-8 weeks, 6 months, and annually at 1,2,3,4, and 5 years. Secondary endpoints to be analyzed are the following: 1. Evidence of Aortic Disease Progression: Monitoring for aneurysm growth \> 5 mm from baseline measurements. 2. Device Failure: Evaluation of device performance, including migration \> 10 mm, device degradation, and loss of device integrity. 3. Endoleaks: Monitoring for the occurrence and classification of endoleaks as outlined in the clinical outcome definitions. 4. Secondary Interventions: Description and analysis of secondary interventions aimed at treating branch vessel stenosis, occlusion, or embolization. 5. Significant Lifestyle-Limiting or Disabling Complications: Assessment and reporting of complications resulting in significant impairment of daily life, such as stroke-induced paralysis (paraplegia). 6. Cardiac Dysfunction: Monitoring and analysis of cardiac events, including myocardial infarction, congestive heart failure, and cardiac ischemia requiring intervention. 7. Renal Events: Evaluation of renal complications, including the need for dialysis, deterioration of renal function, and renal failure. 8. Mesenteric Events: Description and classification of mesenteric complications, such as ischemia and the need for surgical resection. 9. Respiratory Events: Monitoring for respiratory complications, including respiratory failure and prolonged intubation Secondary endpoints will be individually analyzed at 4-8 weeks, 6 months, and annually at 1,2,3,4, and 5 years

Подробное описание

The devices employed in this study are Cook Medical products designed and approved for the treatment of thoracic and abdominal aortic diseases. These devices are constructed with full- thickness woven polyester fabric sewn to self-expanding stainless steel or nitinol Cook-Z stents, utilizing braided polyester and monofilament polypropylene sutures. Available in straight or tapered configurations, both variants are fully stented to ensure stability and the required expansile force for lumen opening during deployment. The devices encompass the Zenith TX2 dissection endovascular grafts and the Zenith Alpha thoracic endovascular grafts. These modular components are used in conjunction with other endovascular grafts to establish suitable proximal and distal sealing zones.

The selection of graft sizes is based on findings from preoperative radiologic studies, including computerized tomography (CT) and, if necessary, conventional angiography. Sizing of Zenith endovascular devices adheres to their respective instructions for use. The chosen outside diameter of the Zenith endovascular graft should be 15-25% larger than the proximal

implantation site. Similarly, the attachment site for the distal implantation is oversized by approximately 15-25%. This optimal graft-to-vessel diameter ratio aims to enhance the likelihood of achieving a secure seal with the vessel wall, mitigating the risk of graft migration, endoleaks, and thrombosis.

The majority of cases involve thoracoabdominal aneurysms, with some encompassing paravisceral and pararenal aneurysms. For the former, fenestrations will be used to preserve flow to visceral vessels, while the latter will involve branches to maintain flow. The goal is to achieve at least 20mm of seal within the normal proximal aorta and 15mm of seal distally in the iliac arteries.

Branches will primarily be used where the aortic diameter at the level of the visceral or renal branches is \>28mm in size. When branches are to be used, 6-8mm fenestrations will be burned 20mm above the target vessel based on centerline measurements described above. A branch will be created by cutting a self-expanding Gore Viabahn stent to 15mm in length and suturing this onto the fenestration in a running fashion using a Gore-Tex suture. The size of the fenestration and the size of the Viabahn stent will be patient on target vessel size and will be created accordingly.

Determination of the proximal graft diameter and graft sizes depends on the measurement of the aneurysm using centerline flow measurements based on axial reconstructions of CT data. All measurements will be made with multi-planar reconstruction (MPR) perpendicular to the long axis of the neck to provide greater understanding of the aneurysm neck diameter. The diameter of all vessels, length to first major branch that cannot be covered, arc length/clock location in comparison to reference vessel (celiac artery), longitudinal distance from reference vessel (celiac artery), angiographic view of the orifice of the vessel for optimal chance of cannulation, size of the aortic flow lumen at the origin of the target visceral vessel, degree of angulation at the vessel origin, and predominant trajectory of the vessel (lateral vs. cranial vs. caudal) will all be recorded in preoperative case planning. The lengths of the proximal, distal and extension components of the appropriate Cook stent graft will be chosen to achieve a recommended minimum of two stent overlap, with three to four stents overlap when possible.

The choice between the Zenith Alpha and TX2 devices depends on the patient's specific circumstances. The Zenith Alpha device is preferred in cases of challenging access (small external iliac artery diameters) to minimize access complications. Additionally, if primarily or only fenestrations are required, the Zenith Alpha device will be chosen due to its more favorable geometry. Otherwise, in the case where branches are chosen, the Cook TX2 device, will be modified due to the ability to presheath branches in a more facile manner.

When branches are to be used, 6-8mm fenestrations will be burned 20mm above the target vessel based on centerline measurements described above. A branch will be created by cutting a self-expanding Gore Viabahn stent to 15mm in length and suturing this onto the fenestration in a running fashion using a Gore-Tex suture. The size of the fenestration and the size of the Viabahn stent will be patient on target vessel size and will be created accordingly. When

fenestrations are used, they will be reinforced with the En Snare endovascular snare using 3-0 ethibond sutures in a running locking manner.

At the physician's discretion, commercially available, off-the-shelf covered stents, specifically, the Atrium Medical Corporation iCAST stent graft (Hudson, NH) the Gore VBX Endoprosthesis or Gore Viabahn (Flagstaff, AZ), may be used to stent visceral vessels targeted by a fenestration. Visceral vessel anatomy and relative orientation will be determined from the imaging data. Important characteristics include the relationship of the renal arteries, the distance between them and the SMA, and the relationship between the celiac and SMA. Careful consideration of angulation is needed, with ostial angles primarily established from axial views, and distances calculated using axial information as well as reconstructions. The diameter of the stent should be 1.0-1.1 times the reference vessel diameter as determined by imaging data. The length of the stent should be selected so that the distal end of the stent does not cross the bifurcation of the targeted vessel.

In the setting of branch vessel tortuosity, bare metal self-expandable stents, specifically the Abbott Vascular Absolute Pro® (Santa Clara, CA), may be used to transition the covered stent graft into the curvature of the target vessel. In addition, the Gore VBX Endoprosthesis (Flagstaff, AZ) platform is much more trackable through curves than the iCAST stent graft (Hudson, NH), enabling stent graft delivery through a steerable sheath, from the groin, for down-going branches. In contrast, the relative stiffness of the iCAST platform makes delivery of the stent graft through a steerable sheath, from the groin, for down-going branches, impossible or extremely difficult.

The proximal edge of a fenestration stent graft will be placed such that 4 mm of stent graft extends into the aortic endograft lumen. This proximal edge will be flared with a Boston Scientific Mustang™ Balloon Dilation Catheter (Maple Grove, MN) to create a seal at the fenestration site. In terms of branches, the proximal edge of the bridging stent will extend 2mm proximal to the suture point of the Viabahn branch that was sutured in place.

In patients who require extensive coverage, procedures will be staged in 2-3 stages, with extent 1 thoracoabdominal aneurysms being repaired in 2 stages, and extent 2 thoracoabdominal aneurysms being repaired in 3 stages. Depending on the location of the landing zone, and size and characteristics of the landing the zone, the proximal landing zone will be the Gore thoracic branch endoprosthesis for aortic pathology requiring zone 2 landing zone, and Cook Alpha or Cook TX2 for zone 3 and 4 landing zones. The Cook Alpha/Cook TX2 will be the modified portion for the visceral component, and in order to minimize device modification, a Gore Excluder will be used as the infrarenal device, with the Gore Iliac Branch Endoprosthesis being used for patients who also have common iliac artery aneurysms.

Like with like devices will be preferentially used whenever possible, and proximal and distal extension will only be used if the devices to not have adequate characteristics to achieve proximal or distal seal.

Patients with extent 1 thoracoabdominal aneurysms will be repaired in 2 stages, with the proximal device being Gore thoracic branch endoprosthesis for aortic pathology requiring zone 2 landing zones, and Cook Alpha or Cook TX2 for zone 3 and 4 landing zones.

For patients with extent II thoracoabdominal aneurysms that require zone 2 or 3 repair, our preference is to split these into 2 procedures, with the first being TEVAR, the second being physician modified endograft and EVAR with/without iliac branch endoprosthesis. In cases without use of the iliac branch endoprosthesis, we plan on using the Gore excluder iliac limbs in order to complete the repair. We believe that this is the safest and most effective way to repair complex extent II thoracoabdominal aneurysms with common iliac disease.

In cases where the Gore Thoracic Branched Endoprosthesis is used for zone 2 seal, distal extension device will either be a Gore Conformable Thoracic Aortic Endovascular Graft (CTAG) or Cook Alpha or TX2, depending on patient anatomy.. This is the only situation where the Gore Conformable Thoracic Aortic Endovascular Graft (CTAG) will be used.

The following methods and materials employed for modifying the Zenith platform mirror those described by Starnes and Oderich. The principal investigator of this proposal as well as the other sub investigators, possess substantial training under Dr. Oderich. This method of physician modification has been successfully implemented in our prior experience at the University of California Davis for creating fenestrated and branched endografts to treat complex aneurysms. The materials utilized in this technique, such as sterile marking pens, ophthalmic cautery, En Snare endovascular snares, prolene sutures, silk sutures, Gore Viabahn self-expanding stents, Gore-Tex sutures, silastic vessel loops, and peel-away sheaths, have established clinical history for such modifications.

1. Following the procedure outlined by Oderich in 2010, each patient's device will be selected in adherence to standard instructions for sizing guidelines. The graft will be unsheathed on a separate table in the operating room. 2. Subsequently, investigators will employ a sterile marking pen to delineate fenestrations or branches' locations based on pre-established length, clock face, and arc angle measurements derived from reconstruction software, as described above. 3. Minor adjustments will be executed in the fenestration area to optimize strut-free fenestrations' utilization whenever feasible. Utilizing an ophthalmic cautery device, the Dacron fabric will be meticulously cauterized. En Snare endovascular snare (Merit Medical, Jordan UT) will reinforce fenestrations, securely hand-sewn into place using 4-0 prolene sutures in a 720-degree running fashion. If a fenestration will serve as a branch, a properly sized Gore self-expanding Viabahn stent will be fashioned, approximately 10-15mm long, and sewn onto the fenestration using Gore 5-0 or 6-0 Stitch. An orientation marker will be placed at the proximal graft edge, and two markers at the distal edge, utilizing Gore stitches. 4. Diameter reducing ties are then used to constrain the device along its posterior border (opposite the SMA and or celiac fenestrations at 6 o'clock) by rerouting one of the existing trifold wires through the graft material at the midpoint of each of the Z stents. The constraining ties are then put down into place over the wire, and the goal is the diameter to be reduced by approximately 60%. 5. The modified device is then resheathed by constraining each stent with a silk tie. Once constrained, the device is serially resheathed using silk tie and a large silastic vessel loop to transition back to the diameter of the original delivery sheath in which the device was packaged. Care is taken to ensure that the markers and branch orientation remain true.

The procedure will be performed in the operating room under local, general, or epidural anesthesia depending on patient factors and agreement of anesthetic plan by the patient, the surgery team, and the anesthesia team. The patient will be positioned on a radiolucent operating room table to permit fluoroscopic examination of the

Вмешательства

  • Устройство Physician Modified Endograft
    The Zenith Alpha and TX2 grafts are tubular grafts made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be opened under sterile conditions and modifications for fenestrations or branches will be created based on the patient's specific anatomy. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm. The graft i

Первичные конечные точки

  • Mortality [Срок оценки: 5 years]
  • Aneurysm rupture [Срок оценки: 5 years]
Вторичные конечные точки (9)
  • Evidence of Aortic Disease Progression [Срок оценки: 5 years]
  • Device Failure [Срок оценки: 5 years]
  • Endoleaks [Срок оценки: 5 years]
  • Secondary Interventions [Срок оценки: 5 years]
  • Significant Lifestyle-limiting or disabling complications [Срок оценки: 5 years]
  • Cardiac dysfunction [Срок оценки: 5 years]
  • Renal events [Срок оценки: 5 years]
  • Mesenteric Events [Срок оценки: 5 years]
  • Respiratory events [Срок оценки: 5 years]

Критерии участия

Критерии включения

  • Patient is > 18 years of age.
  • Patients who are male or non-pregnant female (females of childbearing potential must have a negative pregnancy test prior to enrollment into the study)
  • Patient is able and willing to sign an Institutional Review Board (IRB) approved Informed Consent Form
  • The subject has at least one of the following:
  • . An aortic or aortoiliac aneurysm with a maximum diameter of ≥ 5.5cm for males, ≥ 5.0cm for females
  • Aortic Aneurysm with a history of growth ≥ 0.5 cm in 6 mos.
  • Symptomatic aneurysm
  • Morphology such as saccular aneurysms
  • Aneurysms meeting any of the above criteria a-e above or below the previous endovascular and/or open aortic repairs. Previously placed aortic stent graft or open aortic grafts may serve as seal zones.
  • Cannot be treated with a currently available non-modified approved device.
  • Patient has patent iliac or femoral arteries that will allow endovascular access with the physician modified graft or is suitable for an iliac conduit.
  • Patient has a suitable non-aneurysmal proximal aortic neck length (seal zone) of ≥ 20mm.
  • Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥15mm.
  • The resultant repair should preserve patency in at least one hypogastric artery.
  • Patient has suitable non-aneurysmal distal common iliac diameters between 7 and 20mm.
  • Chronic Dissection with aneurysmal degeneration that meets size criteria as described above for repair
  • Type 1A endoleak requiring extension above the previous repair into the pararenal or paravisceral portion of the aorta to achieve 2 cm of seal.

Критерии исключения

  • patient has a mycotic aneurysm
  • patient has a systemic or local infection that may increase the risk of graft infection.
  • Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment.
  • Subject has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned < 30 days of the endovascular repair.
  • Patient is currently participating in another investigational device or drug clinical trial.
  • Eligible for treatment with FDA-approved marketed device
  • Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturermade device at another institution.
  • Unwilling to comply with the follow-up schedule.
  • Inability or refusal to give informed consent by subject or legal representative. - The subject is pregnant or breastfeeding.
  • Known sensitivities or allergies to the materials of construction of the devices, including stainless steel, polyester, polypropylene, nickel, titanium, or gold. - Known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pretreatment
  • Uncorrectable coagulopathy
  • Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
  • Systemic or local infection that may increase the risk of endovascular graft infection.
  • History of connective tissue disorders (e.g., Marfan Syndrome, Ehlers's Danlos Syndrome) without landing zone created from graft via previous open repair. - Patient has active malignancy with life expectancy of less than 2 years.
  • Patient has a limited life expectancy of less than 2 years.
  • Patient has other medical, social, or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pretreatment, required treatment, and post-treatment procedures and evaluations.
  • Anatomical exclusion criteria such as significant occlusive disease, tortuosity or calcification that would prevent endovascular access.
  • proximal seal site with a circumferential thrombus/atheroma
  • inability to maintain at least one hypogastric artery.
  • shaggy aorta
  • patient is not amenable to a temporary or permanent open surgical or endovascular conduit.
  • Thrombus or excessive calcification within the neck of the aneurysm

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Baylor College of Medicine — Houston

Публикации

  • Chuter TA, Rapp JH, Hiramoto JS, Schneider DB, Howell B, Reilly LM. Endovascular treatment of thoracoabdominal aortic aneurysms. J Vasc Surg. 2008 Jan;47(1):6-16. doi: 10.1016/j.jvs.2007.08.032. Epub 2007 Nov 5. PMID 17980540
  • Schanzer A, Greenberg RK, Hevelone N, Robinson WP, Eslami MH, Goldberg RJ, Messina L. Predictors of abdominal aortic aneurysm sac enlargement after endovascular repair. Circulation. 2011 Jun 21;123(24):2848-55. doi: 10.1161/CIRCULATIONAHA.110.014902. Epub 2011 Apr 10. PMID 21478500
  • Oderich GS. Technique of adding a diameter-reducing wire to the modified TX2 fenestrated stent graft. Vascular. 2010 Nov-Dec;18(6):350-5. doi: 10.2310/6670.2010.00059. PMID 20979923
  • Starnes BW. Physician-modified endovascular grafts for the treatment of elective, symptomatic, or ruptured juxtarenal aortic aneurysms. J Vasc Surg. 2012 Sep;56(3):601-7. doi: 10.1016/j.jvs.2012.02.011. Epub 2012 May 2. PMID 22554425
  • Oderich GS, Fatima J, Gloviczki P. Stent graft modification with mini-cuff reinforced fenestrations for urgent repair of thoracoabdominal aortic aneurysms. J Vasc Surg. 2011 Nov;54(5):1522-6. doi: 10.1016/j.jvs.2011.06.023. Epub 2011 Sep 16. PMID 21925826
  • Tse LW, Steinmetz OK, Abraham CZ, Valenti DA, Mackenzie KS, Obrand DI, Chuter TA. Branched endovascular stent-graft for suprarenal aortic aneurysm: the future of aortic stent-grafting? Can J Surg. 2004 Aug;47(4):257-62. PMID 15362327
  • Starnes BW, Zettervall S, Larimore A, Singh N. Long-Term Results of Physician-Modified Endografts for the Treatment of Elective, Symptomatic, and Ruptured Juxtarenal Abdominal Aortic Aneurysms. Ann Surg. 2024 Oct 1;280(4):633-639. doi: 10.1097/SLA.0000000000006422. Epub 2024 Jun 26. PMID 38920026
  • Starnes BW, Tatum B. Early report from an investigator-initiated investigational device exemption clinical trial on physician-modified endovascular grafts. J Vasc Surg. 2013 Aug;58(2):311-7. doi: 10.1016/j.jvs.2013.01.029. Epub 2013 May 3. PMID 23643560

Идентификаторы

NCT: NCT07224230 · H-57126 · G240006

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗